Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02649751 |
|
Recruitment Status :
Terminated
(The centers have no longer patients. In September 2018, set up of a competitive international study.)
First Posted : January 7, 2016
Last Update Posted : December 13, 2018
|
Sponsor:
University Hospital, Brest
Collaborators:
ManRos Therapeutics
Cyclacel Pharmaceuticals, Inc.
Information provided by (Responsible Party):
University Hospital, Brest
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | July 26, 2018 |
| Actual Study Completion Date : | July 26, 2018 |